XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements and Investments - Additional Information (Detail)
SFr in Millions, $ in Millions
1 Months Ended 3 Months Ended
Apr. 30, 2018
USD ($)
Oct. 31, 2020
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Oct. 31, 2021
USD ($)
Oct. 31, 2021
CHF (SFr)
Oct. 31, 2020
CHF (SFr)
Spinal Kinetics [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Milestone achievement period 5 years   12 months        
Payment for contingent consideration liability     $ 30.0        
Spinal Kinetics [Member] | Other Current Liabilities              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Consideration transferred     11.7        
Maximum [Member] | Spinal Kinetics [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Future milestone payments $ 60.0            
US Food And Drug Administration [Member] | Spinal Kinetics [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Future milestone payments 15.0            
Revenue Milestone [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Future milestone payments       $ 15.0      
Revenue Milestone [Member] | Spinal Kinetics [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Future milestone payments $ 45.0            
Consideration transferred     $ 11.7        
Neo Medical [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Convertible loans   $ 5.0     $ 0.7 SFr 0.6 SFr 4.6
Preferred Stock | Neo Medical [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Amount of Preferred stock consideration   $ 5.0